Evaluating the current evidence for menopausal hormone therapy - QI&CPD - Category 2


2 hrs



# of Credits



QI & CPD - Category 2

Expiry Date


Menopause signifies the end of a woman’s reproductive function following the loss of ovarian follicular activity or surgical removal of both ovaries. Typical symptoms of the decline in estrogen that occurs through the menopause include vasomotor symptoms (VMS) such as hot flushes and night sweats, as well as joint pain, vaginal dryness, sleep disturbances and mood changes. Menopause is often diagnosed retrospectively, when a woman over the age of 40 years has not experienced a spontaneous menstrual bleed for at least 12 months.

This activity has been approved by The Royal Australian College of General Practitioners QI&CPD Program.Total Points: 4.00 Point(s) (Category 2)

Ginni Mansberg
General Practitioner, Sans Souci, NSW),

Professor Susan R Davis
Professor of Women's Health and NHMRC
Senior Principal Research Fellow
Director, Women's Health Research Program
President-elect, International Menopause Society
Dept. of Epidemiology and Preventive Medicine
Monash University)

On completion of this program, participants will be better able to:

  1. Identify patients presenting with common symptoms associated with menopause
  2. Effectively discuss the benefits and risks associated with menopausal hormone therapy (MHT) according to current evidence and Australian protocols
  3. Tailor the choice of MHT to the individual patient
  4. Address patient concerns regarding the benefits and risks of MHT

Related Courses